Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Climb Bio ( (CLYM) ) just unveiled an update.
On January 8, 2026, Climb Bio announced that during 2025 it initiated multiple clinical trials across its two lead antibody programs, including first-patient dosing in the PrisMN Phase 2 trial of budoprutug in primary membranous nephropathy in November 2025, ongoing Phase 1b/2a dosing in immune thrombocytopenia and a global Phase 1b trial in systemic lupus erythematosus, clearance in December 2025 to start a parallel SLE trial in China that will also enroll lupus nephritis patients, and completion of first-cohort dosing for both a subcutaneous formulation of budoprutug and its newly in-licensed anti‑APRIL antibody CLYM116 in healthy volunteers. The company highlighted a “data-rich” 2026, with initial readouts expected across all ongoing budoprutug and CLYM116 studies, alongside refreshed guidance that its cash, cash equivalents and marketable securities are expected to fund operations into 2028, positioning Climb Bio to advance its diversified autoimmune and renal disease portfolio while it expands leadership and board capabilities and deepens its global clinical and regulatory footprint, including through its collaboration with Beijing Mabworks in China.
The most recent analyst rating on (CLYM) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Climb Bio stock, see the CLYM Stock Forecast page.
Spark’s Take on CLYM Stock
According to Spark, TipRanks’ AI Analyst, CLYM is a Neutral.
The score is held back primarily by weak financial performance (no revenue and elevated, worsening cash burn) despite a low-debt balance sheet. Technicals are a key offset with a strong uptrend and constructive momentum. Valuation is less supportive due to losses and no dividend, while corporate events are mixed (encouraging clinical data tempered by legal/contract uncertainty).
To see Spark’s full report on CLYM stock, click here.
More about Climb Bio
Climb Bio, Inc. (Nasdaq: CLYM) is a clinical-stage biotechnology company developing therapeutics for immune-mediated and B‑cell–mediated diseases, with a pipeline led by budoprutug, an anti‑CD19 monoclonal antibody in development for primary membranous nephropathy, immune thrombocytopenia and systemic lupus erythematosus, and CLYM116, an anti‑APRIL monoclonal antibody being developed for IgA nephropathy and other renal indications.
Average Trading Volume: 1,300,117
Technical Sentiment Signal: Buy
Current Market Cap: $259.8M
Learn more about CLYM stock on TipRanks’ Stock Analysis page.